APO RESEARCH · REPORT
Generic Drugs
A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
Product & engineering
Understand the product.
A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
Selected research
Industry Research
Generic Drugs Industry Research Report 2026
Market perspective
A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
Market competition is not intense. Teva, Novartis – Sandoz, Mylan, Sun Pharmaceutical and Aspen are the leaders of the industry, with about 19% market shares.
North America is the largest consumption place, with a consumption market share nearly 44%. Following North America, Europe is the second largest consumption place with the consumption market share of 18%.
Read the full market overview
Report Scope
This report quantifies the global Generic Drugs market in terms of revenue (US$ million) and, where applicable, service volume (K MT), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K MT) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Generic Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Generic Drugs Market by Company
Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
Pharmaniaga Berhad
Hovid Berhad
Duopharma Biotech
Kotra Pharma
HOE Pharmaceutical
Y.S.P. Industries
Generic Drugs Segment by Type
Prescription
Non-Prescription Drugs
Generic Drugs Segment by Application
Hospital
Clinic
Others
Generic Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Generic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Prescription
- Non-Prescription Drugs
Applications
- Hospital
- Clinic
- Others
Companies covered
- Teva
- Novartis - Sandoz
- Mylan
- Sun Pharmaceutical
- Aspen
- Fresenius Kabi
- Pfizer (Hospira)
- Sanofi
- Aurobindo
- Lupin
- Dr. Reddy's
- Apotex
- Cipla
- ENDO (Par Pharmaceutical)
- Stada Arzneimittel
- Krka Group
- Nichi-Iko Pharmaceutical
- Valeant
- Zydus Cadila
- Hikma
- Pharmaniaga Berhad
- Hovid Berhad
- Duopharma Biotech
- Kotra Pharma
- HOE Pharmaceutical
- Y.S.P. Industries
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Generic Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Prescription
- 2.2.3 Non-Prescription Drugs
- 2.3 Generic Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Generic Drugs Breakdown Data by Type
- 3.1 Global Generic Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Generic Drugs Forecasted Market Size by Type (2027-2032)
4 Generic Drugs Breakdown Data by Application
- 4.1 Global Generic Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Generic Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Generic Drugs Market Perspective (2021-2032)
- 5.2 Global Generic Drugs Growth Trends by Region
- 5.2.1 Global Generic Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Generic Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Generic Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Generic Drugs Market Dynamics
- 5.3.1 Generic Drugs Industry Trends
- 5.3.2 Generic Drugs Market Drivers
- 5.3.3 Generic Drugs Market Challenges
- 5.3.4 Generic Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Generic Drugs Players by Revenue
- 6.1.1 Global Top Generic Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Generic Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Generic Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Generic Drugs Head Office and Area Served
- 6.4 Global Generic Drugs Players, Product Type & Application
- 6.5 Global Generic Drugs Manufacturers Established Date
- 6.6 Global Generic Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Generic Drugs Market Size (2021-2032)
- 7.2 North America Generic Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Generic Drugs Market Size by Country (2021-2026)
- 7.4 North America Generic Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Generic Drugs Market Size (2021-2032)
- 8.2 Europe Generic Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Generic Drugs Market Size by Country (2021-2026)
- 8.4 Europe Generic Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Generic Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Generic Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Generic Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Generic Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Generic Drugs Market Size (2021-2032)
- 10.2 South America Generic Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Generic Drugs Market Size by Country (2021-2026)
- 10.4 South America Generic Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Generic Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Generic Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Generic Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Generic Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Teva
- 12.1.1 Teva Company Information
- 12.1.2 Teva Business Overview
- 12.1.3 Teva Revenue in Generic Drugs Business (2021-2026)
- 12.1.4 Teva Generic Drugs Product Portfolio
- 12.1.5 Teva Recent Developments
- 12.2 Novartis - Sandoz
- 12.2.1 Novartis - Sandoz Company Information
- 12.2.2 Novartis - Sandoz Business Overview
- 12.2.3 Novartis - Sandoz Revenue in Generic Drugs Business (2021-2026)
- 12.2.4 Novartis - Sandoz Generic Drugs Product Portfolio
- 12.2.5 Novartis - Sandoz Recent Developments
- 12.3 Mylan
- 12.3.1 Mylan Company Information
- 12.3.2 Mylan Business Overview
- 12.3.3 Mylan Revenue in Generic Drugs Business (2021-2026)
- 12.3.4 Mylan Generic Drugs Product Portfolio
- 12.3.5 Mylan Recent Developments
- 12.4 Sun Pharmaceutical
- 12.4.1 Sun Pharmaceutical Company Information
- 12.4.2 Sun Pharmaceutical Business Overview
- 12.4.3 Sun Pharmaceutical Revenue in Generic Drugs Business (2021-2026)
- 12.4.4 Sun Pharmaceutical Generic Drugs Product Portfolio
- 12.4.5 Sun Pharmaceutical Recent Developments
- 12.5 Aspen
- 12.5.1 Aspen Company Information
- 12.5.2 Aspen Business Overview
- 12.5.3 Aspen Revenue in Generic Drugs Business (2021-2026)
- 12.5.4 Aspen Generic Drugs Product Portfolio
- 12.5.5 Aspen Recent Developments
- 12.6 Fresenius Kabi
- 12.6.1 Fresenius Kabi Company Information
- 12.6.2 Fresenius Kabi Business Overview
- 12.6.3 Fresenius Kabi Revenue in Generic Drugs Business (2021-2026)
- 12.6.4 Fresenius Kabi Generic Drugs Product Portfolio
- 12.6.5 Fresenius Kabi Recent Developments
- 12.7 Pfizer (Hospira)
- 12.7.1 Pfizer (Hospira) Company Information
- 12.7.2 Pfizer (Hospira) Business Overview
- 12.7.3 Pfizer (Hospira) Revenue in Generic Drugs Business (2021-2026)
- 12.7.4 Pfizer (Hospira) Generic Drugs Product Portfolio
- 12.7.5 Pfizer (Hospira) Recent Developments
- 12.8 Sanofi
- 12.8.1 Sanofi Company Information
- 12.8.2 Sanofi Business Overview
- 12.8.3 Sanofi Revenue in Generic Drugs Business (2021-2026)
- 12.8.4 Sanofi Generic Drugs Product Portfolio
- 12.8.5 Sanofi Recent Developments
- 12.9 Aurobindo
- 12.9.1 Aurobindo Company Information
- 12.9.2 Aurobindo Business Overview
- 12.9.3 Aurobindo Revenue in Generic Drugs Business (2021-2026)
- 12.9.4 Aurobindo Generic Drugs Product Portfolio
- 12.9.5 Aurobindo Recent Developments
- 12.10 Lupin
- 12.10.1 Lupin Company Information
- 12.10.2 Lupin Business Overview
- 12.10.3 Lupin Revenue in Generic Drugs Business (2021-2026)
- 12.10.4 Lupin Generic Drugs Product Portfolio
- 12.10.5 Lupin Recent Developments
- 12.11 Dr. Reddy's
- 12.11.1 Dr. Reddy's Company Information
- 12.11.2 Dr. Reddy's Business Overview
- 12.11.3 Dr. Reddy's Revenue in Generic Drugs Business (2021-2026)
- 12.11.4 Dr. Reddy's Generic Drugs Product Portfolio
- 12.11.5 Dr. Reddy's Recent Developments
- 12.12 Apotex
- 12.12.1 Apotex Company Information
- 12.12.2 Apotex Business Overview
- 12.12.3 Apotex Revenue in Generic Drugs Business (2021-2026)
- 12.12.4 Apotex Generic Drugs Product Portfolio
- 12.12.5 Apotex Recent Developments
- 12.13 Cipla
- 12.13.1 Cipla Company Information
- 12.13.2 Cipla Business Overview
- 12.13.3 Cipla Revenue in Generic Drugs Business (2021-2026)
- 12.13.4 Cipla Generic Drugs Product Portfolio
- 12.13.5 Cipla Recent Developments
- 12.14 ENDO (Par Pharmaceutical)
- 12.14.1 ENDO (Par Pharmaceutical) Company Information
- 12.14.2 ENDO (Par Pharmaceutical) Business Overview
- 12.14.3 ENDO (Par Pharmaceutical) Revenue in Generic Drugs Business (2021-2026)
- 12.14.4 ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
- 12.14.5 ENDO (Par Pharmaceutical) Recent Developments
- 12.15 Stada Arzneimittel
- 12.15.1 Stada Arzneimittel Company Information
- 12.15.2 Stada Arzneimittel Business Overview
- 12.15.3 Stada Arzneimittel Revenue in Generic Drugs Business (2021-2026)
- 12.15.4 Stada Arzneimittel Generic Drugs Product Portfolio
- 12.15.5 Stada Arzneimittel Recent Developments
- 12.16 Krka Group
- 12.16.1 Krka Group Company Information
- 12.16.2 Krka Group Business Overview
- 12.16.3 Krka Group Revenue in Generic Drugs Business (2021-2026)
- 12.16.4 Krka Group Generic Drugs Product Portfolio
- 12.16.5 Krka Group Recent Developments
- 12.17 Nichi-Iko Pharmaceutical
- 12.17.1 Nichi-Iko Pharmaceutical Company Information
- 12.17.2 Nichi-Iko Pharmaceutical Business Overview
- 12.17.3 Nichi-Iko Pharmaceutical Revenue in Generic Drugs Business (2021-2026)
- 12.17.4 Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
- 12.17.5 Nichi-Iko Pharmaceutical Recent Developments
- 12.18 Valeant
- 12.18.1 Valeant Company Information
- 12.18.2 Valeant Business Overview
- 12.18.3 Valeant Revenue in Generic Drugs Business (2021-2026)
- 12.18.4 Valeant Generic Drugs Product Portfolio
- 12.18.5 Valeant Recent Developments
- 12.19 Zydus Cadila
- 12.19.1 Zydus Cadila Company Information
- 12.19.2 Zydus Cadila Business Overview
- 12.19.3 Zydus Cadila Revenue in Generic Drugs Business (2021-2026)
- 12.19.4 Zydus Cadila Generic Drugs Product Portfolio
- 12.19.5 Zydus Cadila Recent Developments
- 12.20 Hikma
- 12.20.1 Hikma Company Information
- 12.20.2 Hikma Business Overview
- 12.20.3 Hikma Revenue in Generic Drugs Business (2021-2026)
- 12.20.4 Hikma Generic Drugs Product Portfolio
- 12.20.5 Hikma Recent Developments
- 12.21 Pharmaniaga Berhad
- 12.21.1 Pharmaniaga Berhad Company Information
- 12.21.2 Pharmaniaga Berhad Business Overview
- 12.21.3 Pharmaniaga Berhad Revenue in Generic Drugs Business (2021-2026)
- 12.21.4 Pharmaniaga Berhad Generic Drugs Product Portfolio
- 12.21.5 Pharmaniaga Berhad Recent Developments
- 12.22 Hovid Berhad
- 12.22.1 Hovid Berhad Company Information
- 12.22.2 Hovid Berhad Business Overview
- 12.22.3 Hovid Berhad Revenue in Generic Drugs Business (2021-2026)
- 12.22.4 Hovid Berhad Generic Drugs Product Portfolio
- 12.22.5 Hovid Berhad Recent Developments
- 12.23 Duopharma Biotech
- 12.23.1 Duopharma Biotech Company Information
- 12.23.2 Duopharma Biotech Business Overview
- 12.23.3 Duopharma Biotech Revenue in Generic Drugs Business (2021-2026)
- 12.23.4 Duopharma Biotech Generic Drugs Product Portfolio
- 12.23.5 Duopharma Biotech Recent Developments
- 12.24 Kotra Pharma
- 12.24.1 Kotra Pharma Company Information
- 12.24.2 Kotra Pharma Business Overview
- 12.24.3 Kotra Pharma Revenue in Generic Drugs Business (2021-2026)
- 12.24.4 Kotra Pharma Generic Drugs Product Portfolio
- 12.24.5 Kotra Pharma Recent Developments
- 12.25 HOE Pharmaceutical
- 12.25.1 HOE Pharmaceutical Company Information
- 12.25.2 HOE Pharmaceutical Business Overview
- 12.25.3 HOE Pharmaceutical Revenue in Generic Drugs Business (2021-2026)
- 12.25.4 HOE Pharmaceutical Generic Drugs Product Portfolio
- 12.25.5 HOE Pharmaceutical Recent Developments
- 12.26 Y.S.P. Industries
- 12.26.1 Y.S.P. Industries Company Information
- 12.26.2 Y.S.P. Industries Business Overview
- 12.26.3 Y.S.P. Industries Revenue in Generic Drugs Business (2021-2026)
- 12.26.4 Y.S.P. Industries Generic Drugs Product Portfolio
- 12.26.5 Y.S.P. Industries Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst